Weitz-Schmidt Gabriele
Novartis Pharma AG, Preclinical Research, Basel, Switzerland.
Endothelium. 2003;10(1):43-7. doi: 10.1080/10623320303360.
Lymphocyte function-associated antigen-1 (LFA-1) belongs to the integrin family and plays an important role in leukocyte trafficking and in T-cell activation. Random screening of chemical libraries identified the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor lovastatin as an inhibitor of the LFA-1/intercellular adhesion molecule (ICAM)-1 interaction. The effect of lovastatin on LFA-1 was found to be unrelated to the inhibition of HMG-CoA reductase and to be mediated by lovastatin binding to a novel allosteric site within LFA-1. The biological relevance of LFA-1 inhibition by statins with respect to the overall benefit of this drug class is reviewed. The implications of the statin effect on LFA-1 for future drug design and therapy are discussed.
淋巴细胞功能相关抗原-1(LFA-1)属于整合素家族,在白细胞运输和T细胞激活中起重要作用。对化学文库进行随机筛选,确定3-羟基-3-甲基戊二酰辅酶A(HMG-CoA)还原酶抑制剂洛伐他汀是LFA-1/细胞间黏附分子(ICAM)-1相互作用的抑制剂。发现洛伐他汀对LFA-1的作用与抑制HMG-CoA还原酶无关,而是由洛伐他汀与LFA-1内一个新的变构位点结合介导的。本文综述了他汀类药物抑制LFA-1与该类药物总体益处的生物学相关性。讨论了他汀类药物对LFA-1的作用对未来药物设计和治疗的影响。